Alnylam Pharmaceuticals (ALNY) EBT (2016 - 2025)
Historic EBT for Alnylam Pharmaceuticals (ALNY) over the last 16 years, with Q3 2025 value amounting to $239.0 million.
- Alnylam Pharmaceuticals' EBT rose 31991.75% to $239.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$31.9 million, marking a year-over-year increase of 9005.21%. This contributed to the annual value of -$377.4 million for FY2024, which is 1295.04% up from last year.
- According to the latest figures from Q3 2025, Alnylam Pharmaceuticals' EBT is $239.0 million, which was up 31991.75% from -$35.4 million recorded in Q2 2025.
- In the past 5 years, Alnylam Pharmaceuticals' EBT ranged from a high of $239.0 million in Q3 2025 and a low of -$405.9 million during Q3 2022
- Over the past 5 years, Alnylam Pharmaceuticals' median EBT value was -$188.3 million (recorded in 2021), while the average stood at -$138.3 million.
- Examining YoY changes over the last 5 years, Alnylam Pharmaceuticals' EBT showed a top increase of 31991.75% in 2025 and a maximum decrease of 21662.94% in 2025.
- Quarter analysis of 5 years shows Alnylam Pharmaceuticals' EBT stood at -$260.3 million in 2021, then grew by 20.47% to -$207.0 million in 2022, then skyrocketed by 33.49% to -$137.7 million in 2023, then plummeted by 40.87% to -$194.0 million in 2024, then soared by 223.21% to $239.0 million in 2025.
- Its EBT was $239.0 million in Q3 2025, compared to -$35.4 million in Q2 2025 and -$41.6 million in Q1 2025.